Strand eyes US, Southeast Asia mkts for blood-based cancer screening test
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Strand Life Sciences plans to take its CancerSpot blood test to the US, Southeast Asia, and the Middle East.
- ✓CEO Dr Ramesh Hariharan said, "Our aspiration is global." The firm seeks FDA approval for the test, which screens for 14 cancers.
- ✓They also aim to lower costs for Indian patients.
Story at a Glance
- Category
- Indian Markets
- Reported By
- Business Standard
- Reading Speed
- 4 Minute(s)
- Market Focus
- India Economy
Strand Life Sciences, a subsidiary of Reliance Industries, is looking to expand its blood-based cancer screening test, CancerSpot, into overseas markets, with the US, Southeast Asia and the Middle East among the regions it is targeting.
The company is pursuing US Food and Drug Administration (FDA) approval for the test and expects the regulatory process to reach a key milestone around February-March next year. The US would be its next export market once approval comes through, a company representative said.
"In most regions of the world, one doesn't (require regulatory approval to operate). Our aspiration is global. There is good opportunity in Southeast Asia, in the Middle East and in other parts of the world, which we will be aggressively pursuing," Dr Ramesh Hariharan, chief executive officer of Strand Life Sciences, said.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Business Standard
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.